Forte Biosciences Income Statement (2016-2026) | FBRX

Income Statement Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
Operating items
Research & Development (Quarter)
5.66M1.35M0.69M1.03M1.38M2.49M4.79M7.14M6.37M3.57M4.32M5.59M5.72M5.08M12.54M8.47M15.05M21.59M20.32M22.19M
Selling, General & Administrative (Quarter)
2.04M1.95M1.82M1.99M2.04M2.45M2.07M1.90M3.85M2.81M3.45M7.08M2.76M2.12M3.43M2.96M3.18M2.83M1.97M2.27M
Other Operating Expenses (Quarter)
0.03M0.15M0.15M0.15M0.15M0.15M0.15M0.15M0.15M0.15M
Operating Expenses (Quarter)
7.70M3.30M2.51M3.02M3.42M4.94M6.86M9.03M10.22M6.38M7.80M12.82M8.63M7.35M16.12M11.58M18.38M24.57M22.44M24.60M
Operating Income (Quarter)
-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M-7.35M-16.12M-11.58M-18.38M-24.57M-22.44M-24.60M
EBIT (Quarter)
-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M-7.35M-16.12M-11.58M-18.38M-24.57M-22.44M-24.60M
Non-operating items
Non Operating Investment Income (Quarter)
Interest & Investment Income (Quarter)
Other Non Operating Income (Quarter)
-0.05M-0.04M-0.05M-0.01M0.02M-0.10M0.10M0.14M0.26M-0.61M0.38M0.31M0.24M-1.12M0.47M0.33M0.70M-1.33M0.68M1.47M
Non Operating Income (Quarter)
Net income details
EBT (Quarter)
-8.73M-3.92M-2.82M-3.24M-3.52M-5.00M-6.92M-9.12M-10.22M-6.41M-7.83M-12.85M-8.66M-7.43M-15.66M-24.61M-35.79M-24.61M-21.76M-23.14M
Tax Provisions (Quarter)
0.37M0.19M
Profit After Tax (Quarter)
-7.75M-3.34M-2.57M-3.04M-3.40M-4.88M-6.75M-8.90M-9.96M-5.87M-7.42M-12.51M-8.39M-7.15M-15.66M-11.25M-17.68M-24.77M-22.14M-23.33M
Income from Non-Controlling Interests (Quarter)
0.00M-0.01M0.01M-0.01M-0.01M0.01M0.01M-0.01M-0.01M
Income from Continuing Operations (Quarter)
-8.73M-3.92M-2.82M-3.24M-3.52M-5.00M-6.92M-9.12M-10.22M-6.41M-7.83M-12.85M-8.66M-7.43M-15.66M-24.61M-35.79M-24.61M-22.14M-23.33M
Consolidated Net Income (Quarter)
-8.73M-3.92M-2.82M-3.24M-3.52M-5.00M-6.92M-9.12M-10.22M-6.41M-7.83M-12.85M-8.66M-7.43M-15.66M-24.61M-35.79M-24.61M-22.14M-23.33M
Income towards Parent Company (Quarter)
-8.73M-3.92M-2.82M-3.24M-3.52M-5.00M-6.92M-9.12M-10.22M-6.41M-7.83M-12.85M-8.66M-7.43M-15.66M-24.61M-35.79M-24.61M-22.14M-23.33M
Net Income towards Common Stockholders (Quarter)
-8.73M-3.92M-2.82M-3.24M-3.52M-5.00M-6.92M-9.12M-10.22M-6.41M-7.83M-12.85M-8.66M-7.43M-15.66M-24.61M-35.79M-24.61M-22.14M-23.33M
Additional items
EPS (Basic) (Quarter)
-15.33-7.01-4.77-5.48-4.65-7.20-8.24-10.83-6.75-5.08-4.25-6.96-4.69-2.55-1.37-2.10-2.01-1.67-1.24-1.31
EPS (Diluted) (Quarter)
-15.33-7.01-4.77-5.48-4.65-7.20-8.24-10.83-12.14-7.62-9.30-15.26-10.28-8.83-18.60-29.23-42.52-29.24-26.29-27.71
Shares Outstanding (Quarter)
0.57M0.56M0.59M0.59M0.76M0.70M0.84M0.84M1.51M1.26M1.84M1.85M1.85M2.92M11.40M11.74M17.79M14.72M17.84M17.84M
Shares Outstanding (Diluted) (Quarter)
0.57M0.56M0.59M0.59M0.76M0.70M0.84M0.84M0.84M0.84M0.84M0.84M0.84M0.84M0.84M0.84M0.84M0.84M0.84M0.84M
Shares Outstanding (Entity) (Quarter)
0.59M0.59M0.59M0.59M0.84M0.70M0.84M0.84M1.45M1.45M1.84M1.85M1.85M2.92M11.40M12.28M17.79M12.95M17.84M21.23M
EBITDA (Quarter)
-7.70M-3.30M-2.51M-3.02M-3.42M-4.94M-6.86M-9.03M-10.22M-6.38M-7.80M-12.82M-8.63M-7.35M-16.12M-11.58M-18.38M-24.57M-22.44M-24.60M
Interest Expenses (Quarter)
1.04M0.62M0.30M0.22M0.10M0.07M0.07M0.09M0.01M0.03M0.03M0.03M0.03M0.08M0.82M13.03M17.41M0.04M43.66M34.34M
Tax Rate (Quarter)
-1.71%-0.83%